Two Sigma Advisers LP increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 35.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,811,100 shares of the company's stock after purchasing an additional 470,000 shares during the period. Two Sigma Advisers LP owned 0.88% of Cellebrite DI worth $39,899,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State of Wyoming grew its position in Cellebrite DI by 44.6% in the fourth quarter. State of Wyoming now owns 30,911 shares of the company's stock worth $681,000 after buying an additional 9,530 shares during the last quarter. Silvercrest Asset Management Group LLC acquired a new position in Cellebrite DI in the fourth quarter worth approximately $4,583,000. Polar Capital Holdings Plc grew its position in Cellebrite DI by 61.8% in the fourth quarter. Polar Capital Holdings Plc now owns 448,801 shares of the company's stock worth $9,887,000 after buying an additional 171,404 shares during the last quarter. Man Group plc acquired a new position in Cellebrite DI in the fourth quarter worth approximately $2,385,000. Finally, Nuveen Asset Management LLC grew its position in Cellebrite DI by 38.5% in the fourth quarter. Nuveen Asset Management LLC now owns 585,839 shares of the company's stock worth $12,906,000 after buying an additional 162,886 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
Cellebrite DI Stock Performance
Shares of CLBT opened at $17.02 on Tuesday. The company has a market capitalization of $4.08 billion, a PE ratio of -12.24, a PEG ratio of 4.27 and a beta of 1.44. The company's 50 day moving average price is $19.01 and its 200 day moving average price is $20.25. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same period in the previous year, the company posted $0.08 EPS. Cellebrite DI's revenue was up 20.0% on a year-over-year basis. On average, equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on CLBT shares. Lake Street Capital lifted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $22.43.
Get Our Latest Report on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
